

# Essential Chemicals & Plastics



## Businesses

### Polyolefin Business (Polyethylene, Polypropylene)

#### Polyethylene (PE)

- Synthetic resin that is flexible, highly water- and chemical-resistant, and easy to process (Used in a wide range of products, including packaging materials, such as plastic wrap and food-safe tubes, wire coatings, and plastic film used for greenhouses)



Various products made using polyethylene

#### Polypropylene (PP)

- Synthetic resin with a number of superior properties, including light weight, great workability, durability, heat resistance, and chemical resistance (Used in a wide range of applications, including automobile bumpers, instrument panels, food trays, and home appliances)

### Methyl Methacrylate (MMA) Business (MMA Monomer, MMA Polymer, MMA Sheet)

#### MMA Polymer


- Materials with outstanding transparency and weather resistance (Widely used in optical components such as light guide plates for LED TVs, automotive components, display cases, and outdoor advertisements)

### Licensing Business


- Provision of licenses and sales of catalysts for production methods and technologies cultivated at our plants in Japan and at related companies outside Japan
- A lineup of technologies including not only the propylene oxide-only (PO-only) process for manufacturing PO, but also a hydrochloric acid oxidation process that significantly reduces energy costs and whose byproducts can be recycled as raw materials.

## FY2023 Performance-Related Data


### Sales Revenues and Core Operating Income/ Sales Revenue of SSS Designated Products



### Sales Revenue Ratio by Region



### Invested Capital / ROI



### Transition to Date

Despite the suspension of ethylene production facilities at the Chiba Works and efforts to lift the completion guarantee and stabilize operations for the second phase of the Rabigh project, ROI has fluctuated widely due to volatile petrochemical market conditions. As for invested capital, investments other than business maintenance are limited. In FY2023, ROI significantly deteriorated due to the recognition of impairment losses at the Chiba Works and in Singapore.

### Future Measures

Through fundamental structural reforms, we will advance the optimization of polyolefin production, external collaborations, and business restructuring in Japan and Singapore. For Petro Rabigh, we will form a joint task force with Aramco to improve profitability. Additionally, we will focus on high value-added businesses, such as licensing and catalyst sales, aiming to reduce our dependency on market fluctuations.

## Corporate Business Plan Progress

### Activities aimed at becoming carbon neutral

We will make various efforts to become carbon neutral including collaborations with other companies and academia.

### Major initiatives

- Expand mechanical recycling business
- Pursue technology development in chemical recycling
- Contribute to Recycling Resources

### Progress

- In December 2022, the PMMA chemical recycling demonstration facility began operations, and we are currently advancing technical verification and marketing activities aimed at commercializing the technology by FY2025.
- In December 2023, a demonstration facility for the highly efficient production of methanol from CO<sub>2</sub> was newly established at the Ehime Works.
- In March 2024, the mechanical recycling demonstration facility for automotive waste plastics began operations.

Our Website : Circular System for Plastics Website



### Secure stable revenues via licensing and catalyst business

In accordance with the following three basic strategies, we aim to achieve both stable earnings and sustainable business expansion, while contributing to the realization of carbon neutrality in society.

### Basic strategy

Establish stable revenue base	Expand portfolio	Brush up technology
<ul style="list-style-type: none"> <li>Expand capacity to supply catalysts</li> <li>Expand opportunities to contact potential customers</li> </ul>	<ul style="list-style-type: none"> <li>Quickly establish technologies that reduce environmental impact, expand lineup in license</li> <li>Diversify business models through operational support services</li> </ul>	<ul style="list-style-type: none"> <li>Bolster competitiveness in processes</li> <li>Extend catalyst life and improve costs</li> </ul>

### Progress

- In April 2024, signed a collaboration agreement with KELLOGG BROWN & ROOT, a U.S. engineering company, for the licensing of Sumitomo Chemical's propylene oxide by cumene technology, a technology that is superior in reducing environmental impact.
- In May 2024, signed a collaboration agreement with U.S. licensor Lummus Technology for the licensing and commercialization of Sumitomo Chemical's proprietary PMMA chemical recycling technologies.

Our Website : Technology Licensing Website




## Looking Ahead

We have been advancing business restructuring efforts aimed at ensuring the survival of our domestic petrochemical operations, while also securing stable revenue through our licensing and catalyst business, and undertaking various initiatives toward achieving carbon neutrality.

Going forward, we will steer towards value creation through environmentally friendly technologies, aiming for the development and commercialization of GX technologies centered on plastic resource recycling, as well as business expansion through overseas licensing.

### Restructuring of petrochemical business in Japan and Singapore

We are undertaking various initiatives aimed at restructuring the petrochemical business in both the upstream and downstream sectors in Japan and Singapore.



# IT-related Chemicals / Energy & Functional Materials



## Businesses (IT-related Chemicals)

### Display-related Materials Business

Polarizing films, Touch-sensor panels, Polymer light-emitting materials, Color resists

#### Polarizing films

<b>For Liquid Crystal Displays</b>	Contributes to enhancing display quality, including high brightness, high contrast, and wide viewing angles.
<b>For OLED Displays</b>	Reduces reflections from sunlight and artificial lighting on displays, enabling vibrant color reproduction.

#### Touch-sensor panels

These are locational input components installed in devices such as smartphones.

#### Color resists

Color resists are red, green and blue color materials that form the color filter layers in displays. (Using proprietary dye technology, Sumitomo Chemical's color resists deliver high luminance and high color reproducibility in color filters.)

### Semiconductor Materials Business

Photoresists, Processing chemicals for semiconductors, Compound semiconductor materials

#### Photoresists

Photoresists are photosensitive resins used in the process of creating highly dense/highly integrated circuit patterns on semiconductors and print substrates.

#### Processing chemicals for semiconductors


High-purity, functional chemicals used for cleaning and other processes in semiconductor circuit pattern formation and chip assembly.

#### Compound semiconductor materials

Semiconductor made from a compound of multiple elements, which offer higher frequencies and better voltage endurance characteristics than ordinary silicon semiconductors.

## FY2023 Performance-Related Data (IT-related Chemicals)


### Sales Revenues and Core Operating Income/ Sales Revenue of SSS Designated Products



### Sales Revenue Ratio by Region



### Invested Capital / ROI



### Transition to Date

ROI has been above the hurdle rate since FY2019 due to semiconductor-related investment returns and favorable conditions in display materials. In addition, due to further semiconductor-related new construction expansion, invested capital has been on an upward trend since FY2021.

### Future Measures

We will accelerate structural reforms in response to changes in the competitive environment for polarizing films, which used to be a major product of the sector. Additionally, we are establishing a new semiconductor process chemical facility in the United States and strengthening our production and research and development capabilities in South Korea and developing a compound semiconductor materials business structure, and we will ensure that the results will lead to higher sales and profits.

## Businesses (Energy & Functional Materials)

### Advanced Polymers Business

Liquid crystal polymer (LCP), Polyether sulfone (PES)

#### Liquid crystal polymer (LCP)

A super engineering plastic, which features excellent heat resistance, fluidity, and dimensional stability, and that is mainly used in electronic components, such as connectors.

#### Polyether sulfone (PES)

A super engineering plastic, which features excellent heat resistance, creep resistance, dimensional stability, flame retardance, and water resistance, and that is used in applications such as carbon fiber composite materials in aircraft.



### Specialty Chemical Business

Resorcinol, Plastic additives, Emulsions

#### Resorcinol

Raw materials for various fine chemicals, including adhesives for rubber products such as tires, wood adhesives, flame retardants, and UV absorbers.

### Inorganic Materials Business

High-purity alumina, Low soda alumina, Aluminum hydroxide, High-purity aluminum

#### High-purity alumina

Alumina with a purity of 99.99% or higher, used in lithium-ion secondary battery components and ceramic components for semiconductor manufacturing equipment.

#### High-purity aluminum

Aluminum of various purities, including ultra-high purity up to 99.9999%, used in high-performance fields such as flat panel displays, semiconductor wiring materials, and thermal transfer materials in cryogenic regions.

### Battery Materials Business


Battery separators, Cathode materials

#### Battery separators


Safety components, isolating the positive and negative electrodes of lithium-ion secondary batteries and ensuring ion conductivity between the electrodes by preserving the electrolyte and preventing short-circuits.

## FY2023 Performance-Related Data (Energy & Functional Materials)


### Sales Revenues and Core Operating Income/ Sales Revenue of SSS Designated Products



### Sales Revenue Ratio by Region



### Invested Capital / ROI



### Transition to Date

While we have been actively investing in core business products with expected growth, such as super engineering plastics and high-purity alumina, core operating income has been sluggish due to the global economic slowdown, particularly in China. In FY2023, NOPAT\* further declined, partly due to the impairment loss recorded on the cathode material calcination demonstration facility. As a result, ROI for FY2023 was -7.0%.

### Future Measures

For core business products such as super engineering plastics and high-purity alumina, we will continue to expand sales to meet increasing demand and ensure the success of our investments. At the same time, we will also focus on research and development of next-generation businesses, such as solid-type battery materials, working towards their early commercialization.

\*NOPAT : Net Operating Profit After Tax

## Corporate Business Plan Progress (IT-related Chemicals)

### Display-related materials

#### Maintain competitive advantage by leveraging our own core technologies

While advancing the sophistication of our portfolio, focus on materials for high-end TVs, OLED smartphones, automotive and next-generation displays by differentiating technologies and quality.



Polarizing films for automobile

#### Our Initiatives

- Secure market share in existing high value-added fields
- Capture demand for materials for next-generation displays
- Continue restructuring of commodity LCD materials business

### Progress of structural reforms

#### Polarizing films for large LCDs

- Close lines equal to about 30% of production capacity
- Convert one line to OLED/automotive

#### Touch-sensor and color filter plant

- Completely exit color filters
- Major reforms to touch-sensor production regime

#### Process chemicals for displays

- Sold China LCD chemicals business

### Silicon semiconductor materials

#### Capturing business opportunities in response to market expansion

We will ensure to capture the demand that is expected to steadily expand for the coming several years in the context of increasing CAPEX of data centers to accommodate DX, full-fledged deployment of 5G communications, and electrification/autonomous driving. At the Osaka Works, facilities for the development and evaluation of photoresists for advanced semiconductor processes have become operational, and enhanced facilities for these photoresists have also become operational in South Korea. In addition to deciding to build a new semiconductor process chemicals works in the United States, we are also strengthening our production and research and development capabilities in South Korea. Regarding the back-end semiconductor process, we are leveraging our expertise in high thermal conductivity materials and specialty polymers to advance our efforts toward entering this field.

#### Our Initiatives

- Securely capture growing demand
- Develop products that support innovations in customer processes
- Aim for top share in next-generation EUV with organic molecular resist
- Entering the back-end semiconductor process by leveraging our core technologies

#### Expanding semiconductor market

Compound average growth rate (2019-2025)


**Logic** 13% **Memory** 12%

(Source) WSTS  
Semiconductor Market Forecast June 2024

#### Top-class global market share in semiconductor materials

- Immersion ArF
- High-purity chemicals (IPA, hydrogen peroxide, ammonia water)

#### Schedule for the start of operations of enhanced facilities



### New businesses

#### Creation of new businesses for the next generation

We aim to establish the third business by the late 2020s, following the display-related materials business and the silicon semiconductor materials business. In the power device field, we have begun production of large-diameter gallium nitride substrates and will work to further increase diameter and productivity. We are also engaged in the research and development of new products utilizing the technologies cultivated in our existing two fields, and in FY2023, we launched a glass transparent LED display.

#### Our Initiatives

- Establish business in materials related to telecommunications and sensors
- Launch next-generation power device materials business and contribute to evolution in energy saving technologies

#### Repeater for mobile communications

These are transparent, thin antennas that can be mounted on the windshields of cars. They are compatible with 5G high-speed communication and contribute to improving the communication environment in public transportation and expanding the communication area of mobile devices.




#### Glass transparent LED displays

This is a high-resolution LED display. Compared to existing film types, it offers superior transparency and reliability, contributing to the realization of signage on glass structures.

#### Next-generation power device materials

Gallium nitride substrates for next-generation power devices. It can reduce the size and loss of power conversion circuits used in data center servers, wind power generation, EVs, and other applications. It contributes to carbon neutrality through energy saving.



## Corporate Business Plan Progress (Energy & Functional Materials)

### Concentrate investments and expand business in growth areas

#### Super engineering plastics (LCP)

#### Expand business with increased production capacity. Expand sales into automotive and 5G high-speed telecommunications connectors

With the shift to EVs, customer demand is moving from engine components to automotive connectors and EV motor peripheral components. In addition, as 5G goes into full swing, demand for LCPs that matches the required characteristics is expected to increase. We will develop a production regime to meet such robust demand and focus on expanding sales in growth fields.

#### New facilities commenced operations in FY2023

Approx. **9,000 tons** → **12,000 tons**

#### Our Initiatives

- Considering further plant expansions to meet customer demand.
- Respond to automotive demand and expand sales of 5G high-speed telecommunication connectors

### Battery materials: Battery separators

#### Establishing a framework to achieve higher battery capacity

Demand for lithium-ion secondary batteries is expected to continue growing, particularly for automotive applications. In response to the expanding EV society, we will leverage our accumulated technologies, build a framework to meet customer demand, and promote further expansion of our separator business.

#### Our Initiatives

- Building a framework to meet demand for automotive applications, expand sales to new customers and pursue cost rationalization.
- Focus on expanding sales for consumer use like home appliances, electrically assisted bicycles.

### Develop next generation business

#### Develop new technologies such as solid-type batteries and direct recycling of cathode materials

#### Solid-type batteries

Compared to current lithium-ion secondary batteries, solid-type batteries are safer and are expected to become the next generation of batteries. In an industry-academia joint research program we have succeeded in developing a soft-solid electrolyte, which had been a challenge. We will continue our development efforts for early commercialization.

#### Direct recycling of cathode materials

#### → Contribution to Recycling Resources

#### CO<sub>2</sub> separation membranes

#### → Energy & Functional Materials "CO<sub>2</sub> Separation Membranes" (Investors' Handbook)

### Decide direction for low-profit business

While giving maximum consideration to the impact on stakeholders, we will downsize or withdraw from businesses that we judge to be unprofitable in the future due to changes in the business environment and other factors, in an effort to improve the business portfolio.

#### Our Initiatives

- FY2021 Decided to withdraw from the EPDM business
- FY2022 Decided to withdraw from the dyestuffs business; decided to withdraw from the S-SBR business in Singapore
- FY2024 Decided to sell the overseas aluminum smelting business


### Looking Ahead

In the display-related materials business, we will further increase the proportion of high value-added products, such as materials for OLED displays. In the semiconductor materials business, we will steadily capture the growing demand for silicon semiconductors. Additionally, in the mobility sector, we will continue to offer distinctive products unique to our company. Moving forward, we will integrate our group's ICT and mobility-related businesses, along with the innovative technologies that support them, to propose solutions that accelerate customer innovation.



Semiconductor process chemical works in South Korea

# Health & Crop Sciences



## Businesses

### Agrosolutions Business

Crop protection chemicals, Biorationals, Fertilizers, Rice, etc.

#### Crop protection chemicals

- Insecticides effective on a range of insects causing damage to crops
- Herbicides for a variety of crops
- Fungicides to help control diseases



Various crop protection chemicals, including insecticides and herbicides

#### Biorationals

- Products such as microorganism-based crop protection, plant growth regulators, rhizosphere microbial materials, and biostimulants, all derived from natural sources.

### Environmental Health Business

Household pesticides, Disease control insecticides, Products for controlling tropical diseases, Veterinary drugs, etc.

#### Household pesticides

- Insecticides for indoor and outdoor use (anti-mosquito incense, mosquito repellent, aerosol, etc.)
- Pyrethroid agents used in insect-repellent resin, and other devices

### Feed Additives Business

Methionine

#### Methionine

- Methionine mainly used in poultry feed (Methionine is one of the essential amino acids and acts to promote the growth of animals being raised.)

### Pharma Solution Business

Active pharmaceutical ingredients for small molecule drugs, Nucleic acid medicine, etc.

#### Active pharmaceutical ingredients for small molecule drugs


- Pharmaceutical active ingredients and intermediates supplied to Japanese and foreign pharmaceutical companies

#### Nucleic acid medicine


- Active ingredients for nucleic acid medicine (pharmaceuticals that use DNA or RNA)

## FY2023 Performance-Related Data


### Sales Revenues and Core Operating Income/ Sales Revenue of SSS Designated Products



### Sales Revenue Ratio by Region



### Invested Capital / ROI



### Transition to Date

As a key growth driver for Sumitomo Chemical, we have continued to invest actively. Since FY2022, the full impact of our acquisition in South America has begun to materialize; however, due to the market decline for post-patent products and unfavorable weather conditions, ROI for FY2023 was -0.2%.

### Future Measures

We are pursuing sustainable growth by expanding our global footprint and developing new crop protection chemicals. Additionally, we will strengthen our profitability through measures such as making a full-scale entry into the biostimulant sector.

## Corporate Business Plan Progress

### Portfolio transformation to strengthen group of sustainable products

#### Crop protection chemicals

We put emphasis on environmental regeneration for product development and distribution activity, by choosing no-till farming and seed treatment. Also, we continuously develop and launch new products to strengthen a sustainable product line.

#### Progress of key pipelines

Compound	Application	Current situation
<b>INDIFLIN™</b> (Inpyrfluxam)	Agricultural fungicide for soybean rust, etc.	Launched in 6 countries (Brazil in 2022)
<b>PAVECTO™</b> (Metyltetraprole)	Agricultural fungicide for septoria, etc.	Launched in 2022 (Japan)
<b>Alles™</b> (Oxazosulfyl)	Agricultural insecticide for major pests of rice plants and others	Launched in 2022 (Japan)
<b>Fuseki™</b> (Pyridachlomehyl)	Agricultural fungicide for field crop and vegetable diseases	Launched in 2024 (Japan)
<b>Accede™</b> (ACC)	Agricultural plant growth regulator	Launched in 2022 (the United States)
<b>Rapidicil®</b> (Epyrifenacil)	Herbicides for next-generation weed control systems	Launched in 2024 (Argentina)
<b>Pipeline A</b>	Botanical insecticide for agricultural and household pest control	In Development
<b>Pipeline B</b>	Agricultural fungicide	In Development

#### Biorationals

We will differentiate ourselves from competitors by leveraging our technologies and product lines in areas where we have strengths, such as biorational and botanical products.

#### Our initiatives

- January 2023: Acquired U.S.-based FBSciences, a company specializing in biostimulants
- December 2023: Acquired India's Barrix Agro Sciences, which develops pest control technologies using insect pheromones, through our consolidated subsidiary, Sumitomo Chemical India Ltd.

## Looking Ahead

In the Health & Crop Sciences sector, we have steadily taken steps to expand our business, including the submission of registration applications and market launches for blockbuster candidates such as INDIFLIN™ and Rapidicil®, as well as establishing a footprint in promising markets like Brazil and India. We believe we are now entering a phase where we are harvesting the results of these efforts.

Moving forward, we will further pursue a business strategy focused on regenerative agriculture, expanding our operations through both crop protection chemicals and biorationals.



### Advances and efficiencies in R&D


We identify our focus areas and concentrate our resources in areas where we have strengths, while actively utilizing open innovation.

→ [New Business/R&D \(Investors' Handbook\)](#)

### Strengthen global supply chain

To maximize profits from our expanded global footprint, we will strengthen our supply chain to ensure consistent product quality and security of supply.

### Roll out Integrated Business Planning (IBP) framework



### Secure returns on investments already made

We will work to ensure the recovery of investments made, and aim to achieve ROIC that exceeds the cost of capital as soon as possible.

### Agrosolutions Business in South America

- August 2020: Start of integrated operation of four acquired Nufarm South American subsidiaries and our existing affiliates in South America
- May 2022: Launch of EXCALIA MAX™, a fungicide for soybeans containing the new active ingredient INDIFLIN™ in Brazil
- July 2024: Obtained pesticide registration in Argentina for the new herbicide "Rapidicil®" (active ingredient: epyrifenacil) and products containing the same active ingredient

# Pharmaceuticals



## Businesses

### Prescription Drugs Businesses

#### Major Products

- ORGOVYX® (Prostate cancer)
- MYFEMBREE® (Uterine fibroids/Endometriosis)
- GEMTESA® (Overactive bladder)

#### Major Products in Development

- TP-3654 (Myelofibrosis)
- DSP-5336 (Acute leukemia)
- CT1-DAP001/DSP-1083  
Parkinson's disease (regenerative medicine/cell therapy)

### Diagnostic Drugs Businesses

#### Major Products

- FDGscan® Injection (PET diagnostic product for malignant tumors and other conditions)
- VIZAMYL® Injection (PET diagnostic product for patients suspected of having Alzheimer's disease)

#### Major Products in Development

- NMB58 (PET imaging agent for myocardial perfusion)
- NMK89 (PET imaging agent for pancreatic cancer)


### CDMO (Contract Development and Manufacturing Organization) Business

Combining Sumitomo Pharma's expertise in regenerative medicine/cell therapy with our contract manufacturing knowledge, we are implementing the CDMO business for regenerative medicine/cell therapy products at S-RACMO Co., Ltd.




## FY2023 Performance-Related Data


### Sales Revenues and Core Operating Income



### Sales Revenue Ratio by Region



### Invested Capital / ROI



### Transition to Date

With the loss of U.S. exclusivity for LATUDA® as well as the impact of impairment losses in our North American operations and restructuring costs from the reorganization of our North American subsidiaries, our performance deteriorated and invested capital decreased. As a result, ROI worsened by 34.2 points.

### Future Measures

We aim to achieve core operating income in the black for FY2024 through rigorous cost reductions and further expansion of our three key products—ORGOVYX®, MYFEMBREE®, and GEMTESA®—which are successors to LATUDA®. At the same time, we will work towards building a sustainable growth model.

## Corporate Business Plan Progress

### Establishment of revenue base after the end of LATUDA® exclusivity in the U.S.

As post-LATUDA agents we will maximize revenues from ORGOVYX®, MYFEMBREE®, and GEMTESA®. In addition, the Company will also promote rationalization, including improvement of management efficiency and optimization of business costs.

#### Key Progress

- Completed the reorganization of Sumitomo Pharma's North American subsidiaries
- Promoted thorough streamlining, including workforce optimization in the United States
- The U.S. FDA accepted the supplemental New Drug Application for GEMTESA® to include the treatment of overactive bladder with benign prostatic hyperplasia.

### Strategies for medium- and long-term growth

Looking ahead to what comes after ORGOVYX®, MYFEMBREE®, and GEMTESA®, we will accelerate development, focusing on two promising oncology compounds. In addition, we will seek to maximize product value as quickly as possible by accelerating development and reducing risk, including the active use of external resources. Furthermore, we will achieve medium- to long-term growth by taking on the challenge of developing and commercializing new therapeutic methods, such as regenerative medicine/cell therapy, and Theranostics.

#### Key Progress


- Oncology: At the 2023 American Society of Hematology (ASH) Annual Meeting, we presented positive clinical data from Phase 1/2 trials for two oncology candidates, TP-3654 and DSP-5336.
- DSP-5336: Presented the latest Phase 1/2 trial data at the 2024 European Hematology Association (EHA) Congress and received Fast Track designation from the U.S. FDA.
- CNS Collaboration: We have revised our partnership framework with Otsuka Pharmaceutical Co., Ltd. in the psychiatry and neurology area, focusing on prioritizing key development programs.
- Parkinson's disease: For the regenerative medicine/cell therapy candidate for Parkinson's disease (CT1-DAP001/DSP-1083), we are preparing for a New Drug Application in Japan, while investigator-initiated and company-sponsored trials have commenced in the U.S.
- Universal Influenza Vaccine: Initiated clinical trials for a new universal influenza vaccine candidate.

### Looking Ahead

Our top priority is to achieve core operating income in the black for FY2024 by rigorously streamlining selling, general and administrative expenses, and R&D costs to create a cost structure that aligns with our scale. We will also focus on further expanding the sales of our three key products—ORGOVYX®, MYFEMBREE®, and GEMTESA®—while accelerating the development of two promising oncology pipeline compounds. Additionally, with an eye on medium- to long-term growth, we will place emphasis on next-generation therapies, including regenerative medicine/cell therapy products.

### Theranostics

As a next-generation therapeutic approach, we aim to develop new radiopharmaceuticals that “integrate therapeutics and diagnostics (Theranostics)” by taking advantage of the characteristics of nuclear medicine. In the CRADLE building, our drug research facility, we are working diligently on research and development to deliver optimal medical care to patients as soon as possible.



Adopted by AMED\*2 as CiCLE\*3

\*1 RI: Radioactive isotope  
\*2 AMED: Japan Agency for Medical Research and Development  
\*3 CiCLE: Cyclic Innovation for Clinical Empowerment

#### Key Progress

- Captured the world's first patient images using “NMK89,” which is under development as an imaging agent for pancreatic cancer.

### Strengthen CDMO business

In the fields of next-generation pharmaceuticals such as regenerative medicine/cell therapy and targeted alpha-particle therapy, which are expected to show remarkable growth in the future, we will maximize the synergy between chemistry and pharmaceuticals to aggressively develop our CDMO business.

### S-RACMO Co., Ltd.

S-RACMO, a joint venture of both companies, conducts CDMO business in the field of regenerative medicine/cell therapy by combining Sumitomo Chemical's fundamental technologies for iPS/ES cells and expertise in contract manufacturing of pharmaceuticals with Sumitomo Pharma's experience in advanced manufacturing method development and formulation development gained through multiple projects in the regenerative medicine/cell therapy business. Orders are steadily increasing at FORCE (Facility of Regenerative and Cellular Medicine Organization), a regenerative medicine/cell therapy manufacturing facility that began operations in 2022, and the second production line is currently under construction. We will continue to work to further expand our presence in this fast-growing field.



Sumitomo Pharma Cell Processing Center (United States)